Compare TNXP & RICK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | RICK |
|---|---|---|
| Founded | 2007 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 193.7M |
| IPO Year | 2008 | 1996 |
| Metric | TNXP | RICK |
|---|---|---|
| Price | $9.92 | $26.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 544.8K | 35.2K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | 91.75 | ★ 272.73 |
| EPS | N/A | ★ N/A |
| Revenue | $13,107,000.00 | ★ $144,896,000.00 |
| Revenue This Year | $558.11 | $19.32 |
| Revenue Next Year | $38.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $10.03 | $20.76 |
| 52 Week High | $69.65 | $38.33 |
| Indicator | TNXP | RICK |
|---|---|---|
| Relative Strength Index (RSI) | 35.99 | 47.38 |
| Support Level | N/A | $25.08 |
| Resistance Level | $13.18 | $26.80 |
| Average True Range (ATR) | 0.93 | 0.75 |
| MACD | -0.22 | -0.12 |
| Stochastic Oscillator | 1.20 | 47.72 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
RCI Hospitality Holdings Inc through its subsidiaries, owns and operates establishments that offer live adult entertainment, restaurant, and or bar operations. It also owns and operates a communication company serving the adult nightclub industry. The company's operating business segments are Nightclubs, Bombshells, and Others. It operates nightclubs through the following brands Rick's Cabaret, Vivid Cabaret, Tootsie's Cabaret, Club Onyx, and Jaguars Club. In the Bombshells segment, the company is building a chain of Restaurants and Sports Bars in Dallas, Austin, and Houston, Texas. It derives the majority of revenue from the Nightclubs segment that engages in the sale of alcoholic beverages, food, and merchandise items; service in the form of cover charges, and room rentals.